$LUMO
Lumos Pharma Inc Stock $lumo

$lumo Overview Financials Valuation SEC Filings Company Website

2014 Q2 Form 10-Q Financial Statement

#000112623414000116 Filed on May 08, 2014

Income Statement

Concept	2014 Q2	2014 Q1	2013 Q1
Revenue	$212.0K	$334.0K	$302.0K
YoY Change	-8.62%	10.6%	-35.88%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.900M	$3.300M	$2.000M
YoY Change	26.09%	65.0%	33.33%
% of Gross Profit
Research & Development	$6.475M	$6.387M	$6.343M
YoY Change	28.55%	0.69%	65.61%
% of Gross Profit
Depreciation & Amortization	$200.0K	$300.0K	$200.0K
YoY Change	0.0%	50.0%	14.29%
% of Gross Profit
Operating Expenses	$9.338M	$9.638M	$8.344M
YoY Change	27.9%	15.51%	57.79%
Operating Profit	-$9.127M	-$9.304M	-$8.042M
YoY Change	29.11%	15.69%	66.95%
Interest Expense	$0.00	$0.00	$0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$38.00K	$68.00K	$108.0K
YoY Change	375.0%	-37.04%	-532.0%
Pretax Income	-$9.164M	-$9.236M	-$7.934M
YoY Change	29.49%	16.41%	65.29%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$9.163M	-$9.236M	-$7.934M
YoY Change	29.48%	16.41%	63.86%
Net Earnings / Revenue	-4322.17%	-2765.27%	-2627.15%
Basic Earnings Per Share	-$0.33	-$0.33	-$0.33
Diluted Earnings Per Share	-$0.33	-$0.33	-$0.33
COMMON SHARES
Basic Shares Outstanding	27.87M shares	27.61M shares	25.60M shares
Diluted Shares Outstanding		27.61M shares	23.86M shares

Balance Sheet

Concept	2014 Q2	2014 Q1	2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$77.10M	$84.00M	$64.00M
YoY Change	30.02%	31.25%	78.77%
Cash & Equivalents	$76.86M	$83.71M	$63.28M
Short-Term Investments	$200.0K	$200.0K	$700.0K
Other Short-Term Assets	$400.0K	$700.0K	$700.0K
YoY Change	-20.0%	0.0%	133.33%
Inventory
Prepaid Expenses	$446.0K	$679.0K	$657.0K
Receivables
Other Receivables
Total Short-Term Assets	$78.21M	$85.31M	$65.77M
YoY Change	28.07%	29.72%	76.7%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.456M	$6.434M	$5.889M
YoY Change	8.65%	9.25%	-5.46%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$6.456M	$6.434M	$5.889M
YoY Change	8.65%	9.25%	-5.46%
TOTAL ASSETS
Total Short-Term Assets	$78.21M	$85.31M	$65.77M
Total Long-Term Assets	$6.456M	$6.434M	$5.889M
Total Assets	$84.67M	$91.74M	$71.66M
YoY Change	26.35%	28.03%	64.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$687.0K	$972.0K	$865.0K
YoY Change	-36.15%	12.37%	7.72%
Accrued Expenses	$2.891M	$2.381M	$2.015M
YoY Change	2.63%	18.16%	64.36%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$190.0K	$190.0K	$177.0K
YoY Change	2.15%	7.34%	90.32%
Total Short-Term Liabilities	$3.857M	$3.632M	$3.141M
YoY Change	-7.35%	15.63%	35.97%
LONG-TERM LIABILITIES
Long-Term Debt	$937.0K	$986.0K	$1.136M
YoY Change	-17.01%	-13.2%	-83.54%
Other Long-Term Liabilities	$7.300M	$7.300M	$7.400M
YoY Change	-1.35%	-1.35%	393.33%
Total Long-Term Liabilities	$8.216M	$8.286M	$8.520M
YoY Change	-3.25%	-2.75%	2.17%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.857M	$3.632M	$3.141M
Total Long-Term Liabilities	$8.216M	$8.286M	$8.520M
Total Liabilities	$12.07M	$11.92M	$11.66M
YoY Change	-4.6%	2.2%	9.5%
SHAREHOLDERS EQUITY
Retained Earnings	-$154.4M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$182.0K	$182.0K
YoY Change
Treasury Stock Shares
Shareholders Equity	$72.60M	$79.80M	$60.00M
YoY Change
Total Liabilities & Shareholders Equity	$84.67M	$91.74M	$71.66M
YoY Change	26.35%	28.03%	64.93%

Cashflow Statement

Concept	2014 Q2	2014 Q1	2013 Q1
OPERATING ACTIVITIES
Net Income	-$9.163M	-$9.236M	-$7.934M
YoY Change	29.48%	16.41%	63.86%
Depreciation, Depletion And Amortization	$200.0K	$300.0K	$200.0K
YoY Change	0.0%	50.0%	14.29%
Cash From Operating Activities	-$7.000M	-$6.100M	-$6.600M
YoY Change	42.86%	-7.58%	17.02%
INVESTING ACTIVITIES
Capital Expenditures	-$200.0K	$93.00K	$62.00K
YoY Change	0.0%	50.0%	-91.26%
Acquisitions		$0.00	$0.00
YoY Change
Other Investing Activities	$0.00	$0.00	$700.0K
YoY Change	-100.0%	-100.0%	600.0%
Cash From Investing Activities	-$200.0K	-$93.00K	$685.0K
YoY Change	-166.67%	-113.58%	-203.95%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		-$28.63M	-$49.04M
YoY Change		-41.62%	37331.3%
Debt Paid & Issued, Net		$38.00K	$37.00K
YoY Change		2.7%	60.87%
Cash From Financing Activities	400.0K	$28.58M	$48.97M
YoY Change	33.33%	-41.63%	62676.92%
NET CHANGE
Cash From Operating Activities	-7.000M	-6.100M	-6.600M
Cash From Investing Activities	-200.0K	-$93.00K	$685.0K
Cash From Financing Activities	400.0K	$28.58M	$48.97M
Net Change In Cash	-6.800M	$28.49M	$49.65M
YoY Change	58.14%	-42.62%	-898.12%
FREE CASH FLOW
Cash From Operating Activities	-$7.000M	-$6.100M	-$6.600M
Capital Expenditures	-$200.0K	$93.00K	$62.00K
Free Cash Flow	-$6.800M	-$6.193M	-$6.662M
YoY Change	44.68%	-7.04%	4.93%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	130000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	120000	USD
CY2014Q1	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	251000	USD
CY2013Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	1328000	USD
CY2014Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	972000	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	612000	USD
CY2013Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	130000	USD
CY2014Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	5000	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2861000	USD
CY2014Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2381000	USD
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3858000	USD
CY2014Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4114000	USD
CY2014Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	224941000	USD
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	194038000	USD
CY2014Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2100000	USD
CY2013Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	966000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15000000	USD
CY2014Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4800000	shares
CY2013Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4400000	shares
CY2013Q4	us-gaap	Assets Assets	70557000	USD
CY2014Q1	us-gaap	Assets Assets	91743000	USD
CY2014Q1	us-gaap	Assets Current AssetsCurrent	85309000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	63970000	USD
CY2013Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	9000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	10000	USD
CY2014Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	10000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	61291000	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	63278000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	83713000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20250000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	83713000	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	43028000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	22422000	USD
CY2014Q1	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	249000	USD
CY2013Q4	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	249000	USD
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2014Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27870883	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26573023	shares
CY2014Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27862390	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26573023	shares
CY2014Q1	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	279000	USD
CY2013Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	266000	USD
CY2014Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, and certificates of deposit. Cash and cash equivalents are held by financial institutions and are federally insured up to certain limits. At times, the Company’s cash and cash equivalents balance exceeds the federally insured limits. To limit the credit risk, the Company invests its excess cash primarily in high quality cash equivalents, such as money market funds, or certificates of deposit.</font></div></div>
CY2013Q1	us-gaap	Debt Instrument Decrease Forgiveness DebtInstrumentDecreaseForgiveness	0	USD
	us-gaap	Debt Instrument Decrease Forgiveness DebtInstrumentDecreaseForgiveness	-449000	USD
CY2014Q1	us-gaap	Debt Instrument Decrease Forgiveness DebtInstrumentDecreaseForgiveness	0	USD
CY2014Q1	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	84000	USD
CY2013Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	84000	USD
CY2013Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1321000	USD
CY2014Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1300000	USD
CY2014Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	26900000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	25200000	USD
CY2014Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	256000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4896000	USD
CY2013Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	212000	USD
CY2014Q1	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	145213000	USD
CY2013Q4	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	135977000	USD
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.33
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.33
CY2013Q1	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0	USD
CY2014Q1	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0	USD
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	596000	USD
CY2013Q1	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	0	USD
CY2014Q1	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	0	USD
CY2014Q1	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	0	USD
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-13282000	USD
CY2013Q1	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-747000	USD
CY2013Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-40000	USD
CY2014Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2014Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3251000	USD
CY2013Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2001000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-145626000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	49715000	USD
CY2013Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-7934000	USD
CY2014Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-9236000	USD
CY2014Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2013Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	351000	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-106000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-268000	USD
CY2014Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-125000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	5000	USD
CY2013Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	0	USD
CY2014Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-501000	USD
CY2013Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	335000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3765000	USD
CY2014Q1	us-gaap	Increase Decrease In Notes Receivable Related Parties IncreaseDecreaseInNotesReceivableRelatedParties	0	USD
CY2013Q1	us-gaap	Increase Decrease In Notes Receivable Related Parties IncreaseDecreaseInNotesReceivableRelatedParties	0	USD
	us-gaap	Increase Decrease In Notes Receivable Related Parties IncreaseDecreaseInNotesReceivableRelatedParties	350000	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	251000	USD
CY2014Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-1077000	USD
CY2013Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	261000	USD
CY2014Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-94000	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	679000	USD
CY2013Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-250000	USD
CY2013Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	8000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	219000	USD
CY2014Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	5000	USD
CY2014Q1	us-gaap	Interest Paid InterestPaid	4000	USD
CY2013Q1	us-gaap	Interest Paid InterestPaid	8000	USD
	us-gaap	Interest Paid InterestPaid	180000	USD
CY2014Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	23000	USD
CY2013Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	2000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1802000	USD
CY2013Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	5588000	USD
CY2014Q1	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	5576000	USD
CY2013Q4	us-gaap	Liabilities Liabilities	12230000	USD
CY2014Q1	us-gaap	Liabilities Liabilities	11918000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	70557000	USD
CY2014Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	91743000	USD
CY2014Q1	us-gaap	Liabilities Current LiabilitiesCurrent	3632000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3876000	USD
CY2014Q1	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	1200000	USD
CY2013Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	1200000	USD
CY2014Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	8286000	USD
CY2013Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	8354000	USD
CY2013Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	189000	USD
CY2014Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	190000	USD
CY2013Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1033000	USD
	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	113000	USD
CY2014Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	986000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	48966000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	28582000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	216074000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-93000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	685000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10240000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-6067000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-6623000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-122121000	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-9236000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-145173000	USD
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	-7934000	USD
CY2013Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	USD
CY2014Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-583000	USD
CY2013Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-7934000	USD
CY2014Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-9236000	USD
CY2014Q1	us-gaap	Operating Expenses OperatingExpenses	9638000	USD
	us-gaap	Operating Expenses OperatingExpenses	156971000	USD
CY2013Q1	us-gaap	Operating Expenses OperatingExpenses	8344000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-148140000	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-8042000	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-9304000	USD
CY2013Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	114000	USD
CY2014Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	50000	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	482000	USD
CY2014Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	68000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2514000	USD
CY2013Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	108000	USD
CY2013Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2014Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	182000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	687000	USD
CY2013Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2014Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2013Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	62000	USD
CY2013Q1	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	0	USD
CY2014Q1	nlnk	Reduction Of Ipo Offering Costs ReductionOfIpoOfferingCosts	0	USD
CY2014Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	13531000	USD
CY2013Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9571000	USD
CY2014Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	93000	USD
CY2014Q1	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	0	USD
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0.00	shares
CY2014Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0.00	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2014Q1	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2014Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	679000	USD
CY2013Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	773000	USD
CY2013Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	49035000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	138471000	USD
CY2014Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	28811000	USD
CY2013Q1	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
CY2014Q1	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	67743000	USD
CY2013Q1	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0	USD
CY2014Q1	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0	USD
	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	3479000	USD
CY2013Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
CY2014Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	8215000	USD
CY2013Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	50000	USD
CY2014Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2013Q1	us-gaap	Profit Loss ProfitLoss	-7934000	USD
CY2014Q1	us-gaap	Profit Loss ProfitLoss	-9236000	USD
	us-gaap	Profit Loss ProfitLoss	-145756000	USD
CY2014Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1151000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1133000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6587000	USD
CY2014Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6434000	USD
CY2013Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	32000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	484000	USD
CY2014Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	9000	USD
CY2014Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	38000	USD
CY2013Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	37000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	663000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	107256000	USD
CY2013Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6343000	USD
CY2014Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6387000	USD
CY2014Q1	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2013Q1	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	1629000	USD
	us-gaap	Revenue From Grants RevenueFromGrants	8831000	USD
CY2014Q1	us-gaap	Revenue From Grants RevenueFromGrants	334000	USD
CY2013Q1	us-gaap	Revenue From Grants RevenueFromGrants	302000	USD
CY2013Q1	us-gaap	Share Based Compensation ShareBasedCompensation	966000	USD
CY2014Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2105000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	15014000	USD
CY2014Q1	us-gaap	Stock Issued1 StockIssued1	0	USD
	us-gaap	Stock Issued1 StockIssued1	1654000	USD
CY2013Q1	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2014Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1017217	shares
CY2014Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	280643	shares
CY2014Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	27574000	USD
CY2014Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2105000	USD
CY2014Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1237000	USD
CY2014Q1	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	8493	shares
CY2014Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	182000	USD
CY2014Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	79825000	USD
CY2013Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	58327000	USD
CY2013Q4	us-gaap	Treasury Stock Value TreasuryStockValue	0	USD
CY2014Q1	us-gaap	Treasury Stock Value TreasuryStockValue	182000	USD
CY2014Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div></div>
CY2013Q1	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	2700000	USD
CY2014Q1	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1800000	USD
CY2014Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	27605910	shares
CY2013Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	23860469	shares
CY2014Q1	nlnk	Cash And Cash Equivalents Excluding Certificates Of Deposit CashAndCashEquivalentsExcludingCertificatesOfDeposit	83713000	USD
CY2013Q4	nlnk	Cash And Cash Equivalents Excluding Certificates Of Deposit CashAndCashEquivalentsExcludingCertificatesOfDeposit	61291000	USD
CY2013	nlnk	Financing Received FinancingReceived	67200000	USD
CY2012	nlnk	Financing Received FinancingReceived	1300000	USD
CY2013Q1	nlnk	Forgiveness Of Notes Receivable From Related Parties ForgivenessOfNotesReceivableFromRelatedParties	0	USD
	nlnk	Forgiveness Of Notes Receivable From Related Parties ForgivenessOfNotesReceivableFromRelatedParties	350000	USD
CY2014Q1	nlnk	Forgiveness Of Notes Receivable From Related Parties ForgivenessOfNotesReceivableFromRelatedParties	0	USD
CY2014Q1	nlnk	Increase Decrease In State Research And Development Credit Receivable IncreaseDecreaseInStateResearchAndDevelopmentCreditReceivable	88000	USD
CY2013Q1	nlnk	Increase Decrease In State Research And Development Credit Receivable IncreaseDecreaseInStateResearchAndDevelopmentCreditReceivable	85000	USD
	nlnk	Increase Decrease In State Research And Development Credit Receivable IncreaseDecreaseInStateResearchAndDevelopmentCreditReceivable	417000	USD
CY2013Q4	nlnk	Lab Equipment LabEquipment	3724000	USD
CY2014Q1	nlnk	Lab Equipment LabEquipment	3821000	USD
CY2013Q1	nlnk	Noncash Issuance Of Common Stock Dividend To Preferred Shareholders NoncashIssuanceOfCommonStockDividendToPreferredShareholders	0	USD
	nlnk	Noncash Issuance Of Common Stock Dividend To Preferred Shareholders NoncashIssuanceOfCommonStockDividendToPreferredShareholders	6000	USD
CY2014Q1	nlnk	Noncash Issuance Of Common Stock Dividend To Preferred Shareholders NoncashIssuanceOfCommonStockDividendToPreferredShareholders	0	USD
CY2011Q4	nlnk	Post Ipo Converted Common Stock PostIpoConvertedCommonStock	10719353	shares
CY2011Q4	nlnk	Pre Ipo Convertible Preferred Stock PreIpoConvertiblePreferredStock	14270113	shares
	nlnk	Reduction Of Ipo Offering Costs ReductionOfIpoOfferingCosts	158000	USD
CY2014Q1	nlnk	Royalty Obligation Payable Noncurrent RoyaltyObligationPayableNoncurrent	6000000	USD
CY2014Q1	nlnk	State Research And Development Credit Receivable StateResearchAndDevelopmentCreditReceivable	417000	USD
CY2013Q1	nlnk	Reduction Of Ipo Offering Costs ReductionOfIpoOfferingCosts	0	USD
CY2013Q4	nlnk	Royalty Obligation Payable Noncurrent RoyaltyObligationPayableNoncurrent	6000000	USD
CY2013Q4	nlnk	State Research And Development Credit Receivable StateResearchAndDevelopmentCreditReceivable	329000	USD
CY2013Q4	nlnk	Total Leasehold Improvements And Equipment TotalLeaseholdImprovementsAndEquipment	10445000	USD
CY2014Q1	nlnk	Total Leasehold Improvements And Equipment TotalLeaseholdImprovementsAndEquipment	10548000	USD
CY2014Q1	dei	Amendment Flag AmendmentFlag	false
CY2014Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2014Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2014Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014Q1	dei	Document Period End Date DocumentPeriodEndDate	2014-03-31
CY2014Q1	dei	Document Type DocumentType	10-Q
CY2014Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001126234
CY2014Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	27874204	shares
CY2014Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2014Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2014Q1	dei	Entity Registrant Name EntityRegistrantName	NEWLINK GENETICS CORP
CY2014Q1	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2014Q1	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No

Files In Submission

Name	View Source	Status
0001126234-14-000116-index-headers.html	Edgar Link	pending
0001126234-14-000116-index.html	Edgar Link	pending
0001126234-14-000116.txt	Edgar Link	pending
0001126234-14-000116-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
logo20130930a01a01.jpg	Edgar Link	pending
nlnk-20140331.xml	Edgar Link	completed
nlnk-20140331.xsd	Edgar Link	pending
nlnk-20140331x10q.htm	Edgar Link	pending
nlnk-20140331xex311.htm	Edgar Link	pending
nlnk-20140331xex312.htm	Edgar Link	pending
nlnk-20140331xex321.htm	Edgar Link	pending
nlnk-20140331_cal.xml	Edgar Link	unprocessable
nlnk-20140331_def.xml	Edgar Link	unprocessable
nlnk-20140331_lab.xml	Edgar Link	unprocessable
nlnk-20140331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LUMO
Lumos Pharma Inc Stock $lumo

2014 Q2 Form 10-Q Financial Statement

#000112623414000116 Filed on May 08, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LUMO Lumos Pharma Inc Stock $lumo

2014 Q2 Form 10-Q Financial Statement

#000112623414000116 Filed on May 08, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LUMO
Lumos Pharma Inc Stock $lumo